Potential contribution of 131I-labelled monoclonal anti-CEA antibodies in the treatment of liver metastases from colorectal carcinomas: pretherapeutic study with dose recovery in resected tissues.

Details

Serval ID
serval:BIB_3A65623A20BD
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Potential contribution of 131I-labelled monoclonal anti-CEA antibodies in the treatment of liver metastases from colorectal carcinomas: pretherapeutic study with dose recovery in resected tissues.
Journal
European Journal of Cancer
Author(s)
Ychou M., Ricard M., Lumbroso J., Rougier P., Mach J.P., Buchegger F., Saccavini J.C., Lasser P., Elias D., Eschwege F.
ISSN
0959-8049 (Print)
ISSN-L
0959-8049
Publication state
Published
Issued date
1993
Peer-reviewed
Oui
Volume
29A
Number
8
Pages
1105-1111
Language
english
Abstract
20 patients with liver metastases from colorectal carcinoma undergoing laparotomy received 15-60 mg intravenously, either intact or fragments of, anti-carcinoembryonic antigen (anti-CEA) monoclonal antibodies labelled with 0.55-1.48 GBq (15-40 mCi) of 131I, 3-8 days prior to operation. The uptake measured per gram of metastases ranged from 0.33 to 6.6 x 10(-3%) of injected dose. Tumour to liver uptake ratios ranged from 2 to 33. The radiation dose, estimated in 6 patients (3 of each group), for an extrapolated dose of 3.7 GBq (100 mCi) of 131I ranged from 0.3 to 0.8 Gy in normal liver or spleen (an acceptable estimate for bone marrow radiation dose) and from 3.4 to 8.2 Gy to the hepatic metastases, indicating that probably other therapeutic modalities should be associated with radioimmunotherapy.
Keywords
Antibodies, Monoclonal/administration & dosage, Carcinoembryonic Antigen/immunology, Colorectal Neoplasms/immunology, Half-Life, Humans, Iodine Radioisotopes/metabolism, Liver Neoplasms/immunology, Liver Neoplasms/metabolism, Radioimmunotherapy
Pubmed
Web of science
Create date
25/01/2008 11:28
Last modification date
20/08/2019 13:30
Usage data